share_log

莱美药业(300006.SZ):醋酸特利加压素化学原料药上市申请获批

Laimei Pharmaceutical (300006.SZ): Application for marketing of the chemical ingredient teribapressin acetate approved

Zhitong Finance ·  Dec 30, 2022 18:36

According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (“Laimei Longyu”), a wholly-owned subsidiary of the company, received the approval and issuance of the “Chemical Ingredient Drug Marketing Application Approval Notice” (acceptance number: CYHS2060492) for telibapressin acetate with a specification of 30g/piece from the China Drug Administration.

According to reports, the raw material of teripressin acetate is used in the production of injectable teribapressin preparations. Teripressin is a synthetic vasopressin analog. It is a vasoconstrictor drug among vasoactive drugs. It is mainly used to stop bleeding from cirrhosis, varicose veins, and bleeding. Currently, it is widely used clinically in the treatment of hepatorenal syndrome, cirrhosis, ascites, infectious shock, burns, acute liver failure, cardiac arrest, etc.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment